Merck KGaA

As of March 31, 2026, Merck KGaA carries a market capitalization of 44.75B, placing it among publicly traded companies globally. Its enterprise value stands at 52.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Merck KGaA's next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Merck KGaA has 434.78M shares outstanding.

As of March 31, 2026, Merck KGaA trades at a trailing price-to-earnings ratio of 19.15. The price-to-sales ratio is 2.31, and the price-to-book ratio stands at 1.63.

As of March 31, 2026, Merck KGaA trades at an EV/EBITDA multiple of 9.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.09 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Merck KGaA trades at an EV/FCF ratio of 22.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 52.45B versus a market cap of 44.75B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Merck KGaA maintains a current ratio of 1.51, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.37, indicating elevated leverage, while an interest coverage ratio of 14.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Merck KGaA posted a return on equity (ROE) of 8.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.07, useful for judging operating efficiency across full business cycles. The company generates approximately 309,407.57 in revenue per employee across its workforce of 62,509.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.87 indicates how many times Merck KGaA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Merck KGaA recorded 623.90M in income tax expense. That works out to an effective tax rate of 20.99, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.97B, leaving 2.34B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 19, 2026, Merck KGaA's stock has gained approximately 22.55% over the past 52 weeks. The 50-day moving average sits at 104.09, while the 200-day moving average is 103.61.

Over the twelve months ended March 31, 2026, Merck KGaA generated 19.34B in revenue and converted that into 2.34B in net income, yielding earnings per share of 5.41. EBITDA reached 5.40B, while operating income came in at 3.32B.

As of March 31, 2026, Merck KGaA holds 3.48B in cash and equivalents against 11.11B in total debt, resulting in a net debt position of -2.53B. Total book value stands at 27.45B, with working capital of 4.44B providing operational flexibility.

Merck KGaA produced 3.87B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.83B in capital expenditures, free cash flow totaled 2.04B - equivalent to 4.70 per share.

Over the twelve months ended March 31, 2026, Merck KGaA posted a gross margin of 58.53, reflecting its pricing power and cost economics. The operating margin of 17.15 and net profit margin of 12.08 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Merck KGaA paid dividends of 0.63 per share. The dividend payout ratio of 11.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.57, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.49, meaning Merck KGaA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Merck KGaA's most recent stock split took place on June 30, 2014 with a 1:2 split ratio.

As of March 31, 2026, Merck KGaA has an Altman Z-Score of 3.96, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.